Latest News-Ascentage Pharma Mediaroom_Page

Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918

SUZHOU, China and ROCKVILLE, Md., June 29, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-06-30 10:41 2119

EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

SUZHOU, China, and ROCKVILLE, MD, June 12, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-06-13 07:45 4160

ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

SUZHOU, China, and ROCKVILLE, MD, June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-06-08 08:00 1880

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md., June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-06-08 08:00 1978

ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies

SUZHOU, China, and ROCKVILLE, Md., June 6, 2022 /PRNewswire/ -- scentage Pharma (6855.HK), a global...

2022-06-07 11:30 2330

ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%

SUZHOU, China, and ROCKVILLE, Md., June 6, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-06-07 11:28 2113

ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

SUZHOU, China, and ROCKVILLE, Md., May 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-05-27 10:02 2700

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

SUZHOU, China and ROCKVILLE, Md., May 18, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-05-18 22:06 2736

ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-04-28 08:18 1877

AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

SUZHOU, China and ROCKVILLE, Md., April 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-04-14 08:28 2350

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma

SUZHOU, China, and ROCKVILLE, MD, March 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-03-22 09:15 2132

Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead

SUZHOU, China and ROCKVILLE, Md., March. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glo...

2022-03-21 23:11 3162

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL

SUZHOU, China, and ROCKVILLE, Md., Mar. 14, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-03-15 14:52 1982

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

SUZHOU, China and ROCKVILLE, Md., March 8, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-03-09 07:47 3767

Ascentage Pharma Presented at the 40th Annual J.P. Morgan Healthcare Conference Reporting Steady Transition Towards a Full-Fledged Biopharma

SUZHOU, China and ROCKVILLE, Md., Jan. 11, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-01-12 10:19 2588

Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-01-06 08:30 7536

ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety

SUZHOU, China, and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-12-14 22:04 2813

ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses

SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-12-14 22:04 2558

Ascentage Pharma and Clover Biopharmaceuticals Announce Clinical Collaboration to Evaluate IAP Antagonist, APG-1387, plus the Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, for the Treatment of Peritoneal Carcinomatosis

SUZHOU and CHENGDU, China, and ROCKVILLE, MD., Dec. 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855....

2021-12-09 21:00 2812

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia

SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-12-01 08:00 1699